(CercleFinance.com) – Biosynex announces that Project Merci Merger Sub, a Nevada corporation and subsidiary indirectly wholly owned by Biosynex, has extended the period of takeover bid previously announced to acquire all of the common shares issued and shares of Chembio Diagnostics at a price of $0.45 per Share until April 12
2023, subject to any further extension.
The tender offer was previously scheduled for March 28, 2023.
All of the other terms and conditions of the takeover bid remain unchanged, specifies Biosynex.